Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Sep
22
Today In Oncology
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
Mobile CT Lung Cancer Screening May Expand Access for Underserved Populations
ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer
Losing Weight and Breast Cancer Risk? The GLP-1 Question
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo